Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
JAMA Netw Open ; 4(7): e2117175, 2021 07 01.
Article in English | MEDLINE | ID: covidwho-1306629
Pharmacoepidemiol Drug Saf ; 30(7): 827-837, 2021 07.
Article in English | MEDLINE | ID: covidwho-1192592


The US Food and Drug Administration's Sentinel System was established in 2009 to use routinely collected electronic health data for improving the national capability to assess post-market medical product safety. Over more than a decade, Sentinel has become an integral part of FDA's surveillance capabilities and has been used to conduct analyses that have contributed to regulatory decisions. FDA's role in the COVID-19 pandemic response has necessitated an expansion and enhancement of Sentinel. Here we describe how the Sentinel System has supported FDA's response to the COVID-19 pandemic. We highlight new capabilities developed, key data generated to date, and lessons learned, particularly with respect to working with inpatient electronic health record data. Early in the pandemic, Sentinel developed a multi-pronged approach to support FDA's anticipated data and analytic needs. It incorporated new data sources, created a rapidly refreshed database, developed protocols to assess the natural history of COVID-19, validated a diagnosis-code based algorithm for identifying patients with COVID-19 in administrative claims data, and coordinated with other national and international initiatives. Sentinel is poised to answer important questions about the natural history of COVID-19 and is positioned to use this information to study the use, safety, and potentially the effectiveness of medical products used for COVID-19 prevention and treatment.

COVID-19/therapy , Health Information Management/organization & administration , Product Surveillance, Postmarketing/methods , Public Health Surveillance/methods , United States Food and Drug Administration/organization & administration , Antiviral Agents/therapeutic use , COVID-19/epidemiology , COVID-19/virology , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/adverse effects , Communicable Disease Control/legislation & jurisprudence , Databases, Factual/statistics & numerical data , Electronic Health Records/statistics & numerical data , Health Policy , Humans , Pandemics/prevention & control , Pandemics/statistics & numerical data , United States/epidemiology , United States Food and Drug Administration/legislation & jurisprudence
J Am Med Inform Assoc ; 28(2): 393-401, 2021 02 15.
Article in English | MEDLINE | ID: covidwho-1054313


Our goal is to summarize the collective experience of 15 organizations in dealing with uncoordinated efforts that result in unnecessary delays in understanding, predicting, preparing for, containing, and mitigating the COVID-19 pandemic in the US. Response efforts involve the collection and analysis of data corresponding to healthcare organizations, public health departments, socioeconomic indicators, as well as additional signals collected directly from individuals and communities. We focused on electronic health record (EHR) data, since EHRs can be leveraged and scaled to improve clinical care, research, and to inform public health decision-making. We outline the current challenges in the data ecosystem and the technology infrastructure that are relevant to COVID-19, as witnessed in our 15 institutions. The infrastructure includes registries and clinical data networks to support population-level analyses. We propose a specific set of strategic next steps to increase interoperability, overall organization, and efficiencies.

COVID-19 , Electronic Health Records , Information Dissemination , Information Systems/organization & administration , Public Health Practice , Academic Medical Centers , Humans , Registries , United States